Market Cap 401.19M
Revenue (ttm) 0.00
Net Income (ttm) -45.39M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 588,198
Avg Vol 658,330
Day's Range N/A - N/A
Shares Out 65.02M
Stochastic %K 22%
Beta 0.18
Analysts Strong Sell
Price Target $15.86

Company Profile

Zura Bio Limited, a clinical-stage biotechnology company, develops medicines for immune and inflammatory disorders in the United States. The company develops Tibulizumab, an immunoglobulin G-single-chain variable fragment bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes interleukin (IL)-17A and B-cell activating factor, which is in Phase 2 clinical trial development. It is also developing Torudokimab (ZB-880), a monoclonal antibody that ne...

Industry: Biotechnology
Sector: Healthcare
Phone: 702 825 9872
Website: zurabio.com
Address:
1489 W. Warm Springs Road, Suite 110, Henderson, United States
Breck100
Breck100 Mar. 18 at 7:35 PM
$ZURA 3/17/26 Boothbay Fund Management LLC acquired a new position in shares of Zura Bio Limited (NASDAQ:ZURA - Free Report) during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 824,078 shares of the company's stock, valued at approximately $3,568,000. Boothbay Fund Management LLC owned approximately 1.27% of Zura Bio as of its most recent filing with the Securities and Exchange Commission.
0 · Reply
Pepe_sanchez89
Pepe_sanchez89 Mar. 10 at 2:47 PM
$ZURA anybody in here?
1 · Reply
focafoca99
focafoca99 Mar. 5 at 4:31 PM
$ZURA Warrant-related disclosures this morning
0 · Reply
DARKP00L
DARKP00L Mar. 5 at 11:47 AM
$ZURA 06:39 on Mar. 05 2026 Zura Bio Says Design Of Its Ongoing Phase 2 TibuSURE Clinical Trial Evaluating Tibulizumab In SSc Accepted For Presentation At Systemic Sclerosis World Congress #tradeideas
0 · Reply
DARKP00L
DARKP00L Mar. 5 at 11:40 AM
$ZURA 06:39 on Mar. 05 2026 Zura Bio Says Design Of Its Ongoing Phase 2 TibuSURE Clinical Trial Evaluating Tibulizumab In SSc Accepted For Presentation At Systemic Sclerosis World Congress #tradeideas
0 · Reply
StockConsultant
StockConsultant Mar. 3 at 2:22 PM
$ZURA Bio stock, nice trend, watch for a top of range breakout at https://stockconsultant.com/?ZURA
0 · Reply
Emma_Brownnn
Emma_Brownnn Mar. 2 at 4:02 PM
$ZURA 4hr - 7.85 - 10$ can be long targets if momentum continues, mostly 7.85$ & likely rejection down to the blue arrow, if the light blue Trend Line fails to hold then watch for the Lower Trend to be tested @ the blue arrow towards 3.50$ if that 4.75$ area cannot hold after the Trend
0 · Reply
trading_insight
trading_insight Mar. 2 at 4:01 PM
$ZURA - Higher Low Attempt Structure: Forming higher lows off 6.00; holding 6.50 area. RSI: 50 (balanced). MACD: Curling positive. Key Levels Resistance: 6.80 → 7.10 Support: 6.30 → 6.00 Break Trigger: 7.10 Alpha: Constructive above 6.30. 7.10 clears supply for momentum push.
0 · Reply
trading_insight
trading_insight Mar. 2 at 3:06 PM
$ZURA From a geopolitical lens, small-cap biotech is relatively insulated from oil shocks and Middle East escalation compared to cyclicals, though in a broad risk-off event liquidity can still pressure secondaries; Alpha scenario: post-offering stabilization and risk rotation into defensives drive a push back toward supply. Beta scenario: escalation-driven equity weakness pulls price back toward the lower demand band despite improved cash runway.
0 · Reply
trading_insight
trading_insight Mar. 2 at 3:06 PM
$ZURA is trading near $6.60 after pricing and closing its $134.6M–$144M public offering at $6.25, which explains the recent supply pressure and rejection near the $7.20 supply zone, while strong demand remains layered around $6.20–$6.35; technically, holding above the offering price is constructive and suggests absorption, with upside toward $7.00–$7.20 if buyers regain control, but a break below $6.20 risks a fade toward $5.90. Fundamentally, the capital raise materially strengthens the balance sheet and reduces near-term financing overhang, which is positive longer term despite dilution.
0 · Reply
Latest News on ZURA
Zura Bio to Participate in Upcoming Investor Conferences

Mar 2, 2026, 6:30 AM EST - 16 days ago

Zura Bio to Participate in Upcoming Investor Conferences


Zura Bio Reports Business Updates and Outlook for 2026

Jan 12, 2026, 6:30 AM EST - 2 months ago

Zura Bio Reports Business Updates and Outlook for 2026


Zura Bio Announces Chief Financial Officer Transition

Jul 1, 2025, 6:30 AM EDT - 9 months ago

Zura Bio Announces Chief Financial Officer Transition


Zura Bio to Present at the Jefferies Global Healthcare Conference

May 27, 2025, 6:30 AM EDT - 10 months ago

Zura Bio to Present at the Jefferies Global Healthcare Conference


Zura Bio Announces Participation in June Investor Conferences

May 29, 2024, 6:00 AM EDT - 1 year ago

Zura Bio Announces Participation in June Investor Conferences


Zura Bio Announces Robert Lisicki as CEO and Director

Apr 8, 2024, 6:00 AM EDT - 2 years ago

Zura Bio Announces Robert Lisicki as CEO and Director


Zura Bio Announces Participation at March Conferences

Mar 4, 2024, 6:00 AM EST - 2 years ago

Zura Bio Announces Participation at March Conferences


Zura Bio to Join the Russell 2000® and Russell 3000® Indexes

Jun 23, 2023, 6:30 AM EDT - 2 years ago

Zura Bio to Join the Russell 2000® and Russell 3000® Indexes


Breck100
Breck100 Mar. 18 at 7:35 PM
$ZURA 3/17/26 Boothbay Fund Management LLC acquired a new position in shares of Zura Bio Limited (NASDAQ:ZURA - Free Report) during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 824,078 shares of the company's stock, valued at approximately $3,568,000. Boothbay Fund Management LLC owned approximately 1.27% of Zura Bio as of its most recent filing with the Securities and Exchange Commission.
0 · Reply
Pepe_sanchez89
Pepe_sanchez89 Mar. 10 at 2:47 PM
$ZURA anybody in here?
1 · Reply
focafoca99
focafoca99 Mar. 5 at 4:31 PM
$ZURA Warrant-related disclosures this morning
0 · Reply
DARKP00L
DARKP00L Mar. 5 at 11:47 AM
$ZURA 06:39 on Mar. 05 2026 Zura Bio Says Design Of Its Ongoing Phase 2 TibuSURE Clinical Trial Evaluating Tibulizumab In SSc Accepted For Presentation At Systemic Sclerosis World Congress #tradeideas
0 · Reply
DARKP00L
DARKP00L Mar. 5 at 11:40 AM
$ZURA 06:39 on Mar. 05 2026 Zura Bio Says Design Of Its Ongoing Phase 2 TibuSURE Clinical Trial Evaluating Tibulizumab In SSc Accepted For Presentation At Systemic Sclerosis World Congress #tradeideas
0 · Reply
StockConsultant
StockConsultant Mar. 3 at 2:22 PM
$ZURA Bio stock, nice trend, watch for a top of range breakout at https://stockconsultant.com/?ZURA
0 · Reply
Emma_Brownnn
Emma_Brownnn Mar. 2 at 4:02 PM
$ZURA 4hr - 7.85 - 10$ can be long targets if momentum continues, mostly 7.85$ & likely rejection down to the blue arrow, if the light blue Trend Line fails to hold then watch for the Lower Trend to be tested @ the blue arrow towards 3.50$ if that 4.75$ area cannot hold after the Trend
0 · Reply
trading_insight
trading_insight Mar. 2 at 4:01 PM
$ZURA - Higher Low Attempt Structure: Forming higher lows off 6.00; holding 6.50 area. RSI: 50 (balanced). MACD: Curling positive. Key Levels Resistance: 6.80 → 7.10 Support: 6.30 → 6.00 Break Trigger: 7.10 Alpha: Constructive above 6.30. 7.10 clears supply for momentum push.
0 · Reply
trading_insight
trading_insight Mar. 2 at 3:06 PM
$ZURA From a geopolitical lens, small-cap biotech is relatively insulated from oil shocks and Middle East escalation compared to cyclicals, though in a broad risk-off event liquidity can still pressure secondaries; Alpha scenario: post-offering stabilization and risk rotation into defensives drive a push back toward supply. Beta scenario: escalation-driven equity weakness pulls price back toward the lower demand band despite improved cash runway.
0 · Reply
trading_insight
trading_insight Mar. 2 at 3:06 PM
$ZURA is trading near $6.60 after pricing and closing its $134.6M–$144M public offering at $6.25, which explains the recent supply pressure and rejection near the $7.20 supply zone, while strong demand remains layered around $6.20–$6.35; technically, holding above the offering price is constructive and suggests absorption, with upside toward $7.00–$7.20 if buyers regain control, but a break below $6.20 risks a fade toward $5.90. Fundamentally, the capital raise materially strengthens the balance sheet and reduces near-term financing overhang, which is positive longer term despite dilution.
0 · Reply
trading_momentum_x
trading_momentum_x Mar. 2 at 1:34 PM
$ZURA looks good to me, this one is building right side of base and trying to break out now. Key resistance at that 7 level. If we can clear that, I think this one has a lot of potential for a bigger move up.
0 · Reply
trading_momentum_x
trading_momentum_x Mar. 2 at 11:30 AM
$ZURA looks good to me, this one is building right side of base and trying to break out now. Key resistance at that 7 level. If we can clear that, I think this one has a lot of potential for a bigger move up.
0 · Reply
AAUS1
AAUS1 Mar. 1 at 2:04 PM
$ZURA scratching my head , really lost
0 · Reply
focafoca99
focafoca99 Feb. 27 at 1:35 PM
$ZURA offering done. What’s next — rally or pullback?
0 · Reply
briefingcom
briefingcom Feb. 25 at 12:55 PM
$ZURA: Zura Bio Limited (-4.3%) announces proposed public offering of Class A Ordinary Shares
1 · Reply
StockNews_Live
StockNews_Live Feb. 25 at 11:32 AM
$ZURA Zura Bio Limited announced the pricing of its underwritten public offering of 18,200,000 Class A ordinary shares at a price to the public of $6.25 per share. The gross proceeds to Zura from the offeri…
0 · Reply
JeffreyCress
JeffreyCress Feb. 24 at 9:06 PM
$ZURA offering…
1 · Reply
Quantumup
Quantumup Feb. 24 at 2:55 PM
TD Cowen reiterated $AVTX at a Buy rating and said, Risk/Reward Skewed To Significant Upside For AVTX-009 Phase Il In Large HS Oppy $ABBV $MLTX $ZURA Here's what else TD Cowen had to say in its note to investors: https://x.com/Quantumup1/status/2026309287077658777?s=20
0 · Reply
StockConsultant
StockConsultant Feb. 24 at 2:29 PM
$ZURA Zura Bio stock, watch for a bull flag breakout at https://stockconsultant.com/?ZURA
1 · Reply
BillionerOfKing
BillionerOfKing Feb. 23 at 4:49 PM
$ZURA Current Stock Price: $6.54 Contracts to trade: $7.5 ZURA Mar 20 2026 Call Entry: $0.25 Exit: $0.41 ROI: 63% Hold ~20 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
BioTuesdays
BioTuesdays Feb. 23 at 2:42 PM
$ZURA has announced the appointments of Mark Eisner, MD, PhD, and Ajay Nirula, MD, PhD, to its board of directors (BOD), effective February 21, 2026. Neil Graham, MBBS, MD, MPH, stepped down from the BOD on that date. https://biotuesdays.com/2026/02/23/drs-mark-eisner-and-ajay-nirula-join-zura-bios-bod/
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Feb. 21 at 10:47 AM
$ZURA RSI: 59.63, MACD: 0.2412 Vol: 0.23, MA20: 6.14, MA50: 5.34 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply